Craneware plc
("Craneware" or the "Company")
Total Voting Rights
2 October 2024 - Following recent share option exercise transactions by employees, on 30 September 2024 the Company transferred a total of 439 Ordinary Shares previously held in treasury to satisfy those share option exercise transactions.
As a result, the Company's issued share capital now consists of 35,542,169 Ordinary Shares, of which 199,453 remain held in treasury. Accordingly, the total number of Ordinary Shares in the Company with voting rights is 35,342,716. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
|
Craneware plc |
+44 (0)131 550 3100 |
|
Keith Neilson, CEO |
|
|
Craig Preston, CFO |
|
|
|
|
|
Alma Strategic Communications (Financial PR) |
+44 (0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon |
craneware@almastrategic.com |
|
|
|
|
Peel Hunt (NOMAD and Joint Broker) |
+44 (0)20 7418 8900 |
|
Neil Patel, Benjamin Cryer, Kate Bannatyne |
|
|
|
|
|
Investec Bank PLC (Joint Broker) |
+44 (0)20 7597 5970 |
|
Patrick Robb, Henry Reast, Shalin Bhamra |
|
|
|
|
|
Berenberg (Joint Broker) |
+44 (0)20 3207 7800 |
|
Mark Whitmore, Richard Andrews, Dan Gee-Summons |
|
About Craneware
The Craneware Group (AIM:CRW.L), is the market leader in value cycle solutions. For 25 years, we have collaborated with U.S. healthcare providers to optimize revenue integrity, pricing intelligence, decision support, labor productivity, business of pharmacy, and 340B program management.
Customers choose Trisus®, a HITRUST- and SOC2 Type II-certified, SaaS platform, to achieve operational and financial excellence in pursuit of their healthcare mission - delivering quality care to their communities. The Craneware Group - Transforming the Business of Healthcare.
Learn more at www.thecranewaregroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
